179 related articles for article (PubMed ID: 11261809)
1. The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics.
Greig NH; De Micheli E; Holloway HW; Yu QS; Utsuki T; Perry TA; Brossi A; Ingram DK; Deutsch J; Lahiri DK; Soncrant TT
Acta Neurol Scand Suppl; 2000; 176():74-84. PubMed ID: 11261809
[TBL] [Abstract][Full Text] [Related]
2. An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.
Greig NH; Sambamurti K; Yu QS; Brossi A; Bruinsma GB; Lahiri DK
Curr Alzheimer Res; 2005 Jul; 2(3):281-90. PubMed ID: 15974893
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors.
Darreh-Shori T; Hosseini SM; Nordberg A
J Alzheimers Dis; 2014; 39(2):423-40. PubMed ID: 24217282
[TBL] [Abstract][Full Text] [Related]
4. Preclinical investigation of the topical administration of phenserine: transdermal flux, cholinesterase inhibition, and cognitive efficacy.
Utsuki T; Uchimura N; Irikura M; Moriuchi H; Holloway HW; Yu QS; Spangler EL; Mamczarz J; Ingram DK; Irie T; Greig NH
J Pharmacol Exp Ther; 2007 Apr; 321(1):353-61. PubMed ID: 17255466
[TBL] [Abstract][Full Text] [Related]
5. Anticholinesterase and pharmacokinetic profile of phenserine in healthy elderly human subjects.
Greig NH; Ruckle J; Comer P; Brownell L; Holloway HW; Flanagan DR; Canfield CJ; Burford RG
Curr Alzheimer Res; 2005 Oct; 2(4):483-92. PubMed ID: 16248851
[TBL] [Abstract][Full Text] [Related]
6. Phenserine: a physostigmine derivative that is a long-acting inhibitor of cholinesterase and demonstrates a wide dose range for attenuating a scopolamine-induced learning impairment of rats in a 14-unit T-maze.
Iijima S; Greig NH; Garofalo P; Spangler EL; Heller B; Brossi A; Ingram DK
Psychopharmacology (Berl); 1993; 112(4):415-20. PubMed ID: 7871051
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
Jann MW; Shirley KL; Small GW
Clin Pharmacokinet; 2002; 41(10):719-39. PubMed ID: 12162759
[TBL] [Abstract][Full Text] [Related]
8. Effects of bis(7)-tacrine, a novel anti-Alzheimer's agent, on rat brain AChE.
Wang H; Carlier PR; Ho WL; Wu DC; Lee NT; Li CP; Pang YP; Han YF
Neuroreport; 1999 Mar; 10(4):789-93. PubMed ID: 10208549
[TBL] [Abstract][Full Text] [Related]
9. Phenserine and ring C hetero-analogues: drug candidates for the treatment of Alzheimer's disease.
Greig NH; Pei XF; Soncrant TT; Ingram DK; Brossi A
Med Res Rev; 1995 Jan; 15(1):3-31. PubMed ID: 7898167
[No Abstract] [Full Text] [Related]
10. The effect of heptyl-physostigmine, a new cholinesterase inhibitor, on the central cholinergic system of the rat.
De Sarno P; Pomponi M; Giacobini E; Tang XC; Williams E
Neurochem Res; 1989 Oct; 14(10):971-7. PubMed ID: 2608162
[TBL] [Abstract][Full Text] [Related]
11. Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats.
Kosasa T; Kuriya Y; Matsui K; Yamanishi Y
Eur J Pharmacol; 1999 Sep; 380(2-3):101-7. PubMed ID: 10513568
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of action of cholinesterase inhibitors in Alzheimer's disease.
Håkansson L
Acta Neurol Scand Suppl; 1993; 149():7-9. PubMed ID: 7907455
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease.
Asthana S; Greig NH; Hegedus L; Holloway HH; Raffaele KC; Schapiro MB; Soncrant TT
Clin Pharmacol Ther; 1995 Sep; 58(3):299-309. PubMed ID: 7554703
[TBL] [Abstract][Full Text] [Related]
14. The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice.
Lahiri DK; Chen D; Maloney B; Holloway HW; Yu QS; Utsuki T; Giordano T; Sambamurti K; Greig NH
J Pharmacol Exp Ther; 2007 Jan; 320(1):386-96. PubMed ID: 17003227
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease.
Yu Q; Holloway HW; Utsuki T; Brossi A; Greig NH
J Med Chem; 1999 May; 42(10):1855-61. PubMed ID: 10346939
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine.
Kamal MA; Klein P; Luo W; Li Y; Holloway HW; Tweedie D; Greig NH
Neurochem Res; 2008 May; 33(5):745-53. PubMed ID: 17985237
[TBL] [Abstract][Full Text] [Related]
17. Computational and Kinetic Studies of Acetylcholine Esterase Inhibition by Phenserine.
Tabrez S; Damanhouri GA
Curr Pharm Des; 2019; 25(18):2108-2112. PubMed ID: 31258059
[TBL] [Abstract][Full Text] [Related]
18. Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain.
Rakonczay Z
Acta Biol Hung; 2003; 54(2):183-9. PubMed ID: 14535624
[TBL] [Abstract][Full Text] [Related]
19. Phenserine.
Klein J
Expert Opin Investig Drugs; 2007 Jul; 16(7):1087-97. PubMed ID: 17594192
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and drug interactions of cholinesterase inhibitors administered in Alzheimer's disease.
Crismon ML
Pharmacotherapy; 1998; 18(2 Pt 2):47-54; discussion 79-82. PubMed ID: 9543465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
